Novavax-Serum Institute to produce for 200 crore Covid-19 va
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Novavax Inc on 15 September announced that it has revised its deal with world's largest vaccine manufacturing company Serum Institute of India (SII) in order to produce 2 billion doses of Covid-19 vaccines.

In August, Novavax signed a deal with Pune-based Serum Institute to produce a minimum of one billion doses of its vaccine candidate for low-and middle-income countries and India.

However, as a part of the expanded agreement, Serum Institute will also manufacture the antigen component of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate.

“We continue to work with extraordinary urgency to develop our vaccine, now in Phase 2 clinical trials, and for which we anticipate starting Phase 3 efficacy trials around the world in the coming weeks," the company said in a statement.

US-based Novavax's vaccine is in mid-stage trials after an early-stage trial showed it produced high levels of antibodies against the novel coronavirus.

Moreover, the Indian Council of Medical Research (ICMR) and SII have also partnered for clinical development of a glycoprotein subunit nanoparticle adjuvanted vaccine developed by Novavax.

The trial will be initiated in the second half of October after the vaccine is manufactured by SII. The trial is led by ICMR-National AIDS Research Institute (NARI), Pune.

Source: https://www.livemint.com/news/world/novavax-serum-institute-to-produce-for-200-crore-covid-19-vaccine-doses-11600167943161.html
Dr. T●●●●z H●●●●●●i and 6 others like this2 shares
Like
Comment
Share